Skip to main content

Table 2 Baseline serum cytokines in Cohort 1 (hepatic arterial infusion chemotherapy-treated patients)

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Cytokines (pg/mL, mean ± SE) CR/PR group SD/PD group P-valuea
EGF 20.8 ± 3.8 21.6 ± 3.0 0.882
FGF 2.84 ± 1.63 8.40 ± 2.53 0.134
HGF 523.9 ± 50.3 739.8 ± 71.6 0.043
IFN-γ 0.109 ± 0.064 1.343 ± 0.699 0.203
IL-10 0.813 ± 0.169 1.239 ± 0.219 0.193
IL-12 (p70) 8.41 ± 1.17 10.77 ± 1.05 0.164
IL-2 0.297 ± 0.092 1.118 ± 0.568 0.299
IL-4 0.586 ± 0.170 1.213 ± 0.197 0.038
IL-5 17.3 ± 5.5 15.6 ± 2.0 0.718
IL-6 10.90 ± 3.94 9.05 ± 1.65 0.614
IL-8/CXCL8 61.3 ± 37.1 18.7 ± 2.7 0.119
CXCL10 358.3 ± 41.1 359.1 ± 30.3 0.988
CXCL9 176.6 ± 14.0 205.8 ± 30.6 0.502
PDGF-BB 152.5 ± 20.9 193.6 ± 24.3 0.265
SCF 14.1 ± 1.3 16.4 ± 1.0 0.189
SDF-1 60.3 ± 26.3 13.1 ± 5.0 0.022
TGF-β 5.17 ± 3.42 1.64 ± 0.71 0.188
TGF-α 34.0 ± 23.8 14.2 ± 6.3 0.307
TNF-α 1.23 ± 0.31 1.87 ± 0.30 0.184
VEGF-A 65.1 ± 9.4 83.6 ± 6.9 0.116
  1. CR complete response, PD progressive disease, PR partial response, SD stable disease, SE standard error
  2. aUnpaired t-tests